ImmPACT Bio’ IMPT-514 Receives the US FDA’s Fast Track Designation for Refractory Lupus Nephritis and Systemic Lupus Erythematosus
Shots:
- The US FDA has granted FTD to IMPT-514 for the treatment of patients with active refractory LN and SLE. The first patient dosing in the P-Ib/II trial for the treatment of active, refractory SLE is expected in early 2024
- Additionally, IMPT-514 showed potent elimination of autologous B cells and a moderate cytokine profile in preclinical studies & was successfully and efficiently manufactured from heavily immunosuppressed patients with lupus nephritis and systemic lupus erythematosus
- IMPT-514 is a CD19/CD20-targeting CAR T-cell therapy that uses a potent bispecific CAR and a 4-1BB costimulatory domain
Ref: PR Newswire | Image: ImmPACT Bio
Related News:- Kezar Life Sciences Entered into a Collaboration and License Agreement with Everest Medicines for Zetomipzomib to Treat Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
